Smallpox :: New plasma-derived product to treat complications of smallpox vaccin
FDA has approved Vaccinia Immune Globulin Intravenous (VIGIV) — the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination. VIGIV, licensed to DynPort Vaccine Company LLC, in Frederick, Md., is made from the pooled plasma of donors who received booster immunizations with the licensed smallpox vaccine — Dryvax. This plasma contains increased levels of protective antibodies against the vaccinia virus, the live virus used in the currently available smallpox vaccine. The vaccinia virus is similar to the smallpox virus, but does not cause smallpox.